# Cystic Fibrosis Translational Research in the Post-CFTR Modulator Era

> **NIH NIH P30** · SEATTLE CHILDREN'S HOSPITAL · 2021 · $1,214,759

## Abstract

This P30 Cystic Fibrosis (CF) Research and Translational Core Center (CFRTC) is located at the
University of Washington School of Medicine (UWSOM) and its affiliated institution, Seattle Children’s
Research Institute (SCRI). This proposed P30 center program enhances an existing robust basic and clinical
research base at these institutions totaling over $37 million direct costs in current research funding ($23.7 in
DDK related funding representing 64% of total) and an additional $29 million in CF related infrastructure
funding and includes 58 UW/SCRI and affiliate investigators in 19 departments and/or divisions across 4
Schools (Medicine: 51, Public Health: 3, Pharmacy: 2, Dentistry: 1). The UWSOM has a long history of
excellence in CF-related translational research and microbiology with particular focus on gastrointestinal
microbiome as well as CF related Diabetes (CFRD) in the past 5 years. The research for this P30 will focus on
four Specific Aims: 1) Enhance the research cores and other infrastructure for CF research in NIDDK
interest areas that promotes creative, interdisciplinary and clinically-impactful CF research. 2) Provide
expertise to researchers world-wide to design innovative clinical studies that determine best practice and
develop new therapeutic approaches to correct dysfunctional CFTR and its secondary consequences. 3)
Direct a successful pilot and feasibility grant program that attracts young and “new to CF”
investigators, emphasizing support for investigators studying CF-related diabetes, GI disease, renal
physiology, and other extra-pulmonary disease manifestations. 4) Train and mentor the next generation of
laboratory, clinical, and biostatistical science leaders in CF locally and across the US.
 The center will be led by Co-PDs, Bonnie Ramsey, MD, Professor of Pediatrics and Pradeep Singh
MD, Professor of Microbiology and Medicine, CF investigators both internationally recognized in their
respective areas of clinical research and bacterial pathogenesis. They will be supported by other key
leadership: Lucas Hoffman MD, PhD, Professor of Pediatrics and Microbiology, Charles Frevert, DVM, ScD,
Professor of Department of Comparative Medicine, Christopher Goss MD, MPH, Professor of Medicine and
Pediatrics, Stephen Salipante MD, PhD, Associate Professor of Laboratory Medicine, Colin Manoil PhD,
Professor of Genome Sciences and David Nichols, Associate Professor of Pediatrics. The center will consist of
an Administrative Core (Ramsey and Singh, Directors) and three biomedical cores, Host-Microbe (Hoffman
and Frevert, Directors), Genomics (Salipante and Manoil, Directors) and Clinical Translational (Goss and
Ramsey, Directors). The CFRTC will operate a Pilot and Feasibility (P&F) program led by Drs. Singh and
Nichols. Three newly approved P&F projects are included in the current proposal chosen through a competitive
process and approved by the Internal Advisory Board.

## Key facts

- **NIH application ID:** 10237338
- **Project number:** 5P30DK089507-12
- **Recipient organization:** SEATTLE CHILDREN'S HOSPITAL
- **Principal Investigator:** Bonnie W Ramsey
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,214,759
- **Award type:** 5
- **Project period:** 2010-07-06 → 2025-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10237338

## Citation

> US National Institutes of Health, RePORTER application 10237338, Cystic Fibrosis Translational Research in the Post-CFTR Modulator Era (5P30DK089507-12). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10237338. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*